OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers

Hormone and Metabolic Research

Volumn 43, Issue 13, 2011, Pages 944-949

  Sipos, W ^a   Zysset, P ^b   Kostenuik, P ^c   Mayrhofer, E ^a   Bogdan, C ^d   Rauner, M ^e   Stolina, M ^c   Dwyer, D ^c   Sommerfeld Stur, I ^a   Pendl, G ^f   Resch, H ^g   Dallara, E ^b   Varga, P ^b   Pietschmann, P ^d  

^a Clinic for Swine   (Austria)

^b VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^c Amgen Thousand   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f AMGEN INC   (United States)

^g II Medical Department   (Austria)

Author keywords

bone metabolism; RANKL inhibition; trabecular architecture

Indexed keywords

CALCIUM; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHORUS; RECOMBINANT OSTEOPROTEGERIN FC; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE METABOLISM; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; EXPERIMENTAL PIG; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PLASTICITY; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; CALCIUM; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; OSTEOPROTEGERIN; PHOSPHORUS; RANK LIGAND; SWINE;

ANIMALIA; SUIDAE;

EID: 83155181292     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1295463     Document Type: Article

References (33)

1. Pietschmann P, Rauner M, Sipos W. Osteoporosis: an age-related and gender-specific disease a mini-review. Gerontology: 2008; 55 3 12
2. Kostenuik P J, Nguyen H Q, McCabe J, Warmington K S, Kurahara C, Sun N, Chen C, Li L, Cattley R C, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan H L, Asuncion F, Li X, Ominsky M S, Stolina M, Dwyer D, Dougall W C, Hawkins N, Boyle W J, Simonet W S, Sullivan J K. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res: 2009; 24 182 185
3. Guidelines for Preclinical and Clinical Evaluation of Agents Used for the prevention or Treatment of Postmenopausal osteoporosis, Division of Metabolism and Endocrine Drug Products, U.S. Food and Drug Administration 1994
4. Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem: 2008; 15 127 136 (Pubitemid 351234616)
5. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan C R, Stouch B, Martin S, Kostenuik P J. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res: 2003; 18 852 858 (Pubitemid 37294968)
6. Ominsky M S, Li X, Asuncion F J, Barrero M, Warmington K S, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan H L, Corbin T, McCabe J, Simonet W S, Ke H Z, Kostenuik P J. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res: 2008; 23 672 682 (Pubitemid 351575021)
7. 3 J Vet Med A: 2005; 52 382 387 (Pubitemid 41641031)
8. Sipos W, Kralicek E, Rauner M, Duvigneau J C, Worliczek H L, Schamall D, Hartl R T, Sommerfeld-Stur I, DallAra E, Varga P, Resch H, Schwendenwein I, Zysset P, Pietschmann P. Bone and cellular immune system of multiparous sows are insensitive to ovariectomy and nutritive calcium shortage. Horm Metab Res: 2011; 43 404 409
9. Allen M J. Biochemical markers of bone metabolism in animals: uses and limitations. Vet Clin Pathol: 2003; 32 101 113 (Pubitemid 37281086)
10. Parfitt A M, Drezner M K, Glorieux F H, Kanis J A, Malluche H, Meunier P J, Ott S M, Recker R R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res: 1987; 2 595 610
11. Cummings S R, San Martin J, McClung M R, Siris E S, Eastell R, Reid I R, Delmas P, Zoog H B, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med: 2009; 361 756 765
12. Stopeck A T, Lipton A, Body J J, Steger G G, Tonkin K, de Boer R H, Lichinitser M, Fujiwara Y, Yardley D A, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol: 2010; 28 5132 5139
13. Min H, Morony S, Sarosi I, Dunstan C R, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik P J, Lacey D L, Boyle W J, Simonet W S. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med: 2000; 192 463 474 (Pubitemid 30666247)
14. Rodeo S A, Kawamura S, Ma B, Deng X H, Sussman P S, Hays P, Ying L. The effect of osteoclastic activity on tendon-to-bone healing: An experimental study in rabbits. J Bone Joint Surg: 2007; 89 2250 2259 (Pubitemid 47606173)
15. Kim H, Morgan-Bagley S, Kostenuik P J. RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis. J Bone Miner Res: 2006; 21 1946 1954 (Pubitemid 44851571)
16. Ominsky M S, Kostenuik P J, Cranmer P, Smith S Y, Atkinson J E. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int: 2007; 18 1073 1082 (Pubitemid 47020009)
17. Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki S I, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone: 1998; 23 495 498 (Pubitemid 28529453)
18. Tomoyasu A, Goto M, Fujise N, Mochizuki S I, Yasuda H, Morinaga T, Tsuda E, Higashio K. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun: 1998; 245 382 387 (Pubitemid 28418509)
19. Bekker P J, Holloway D, Nakanishi A, Arrighi M, Leese P T, Dunstan C R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res: 2001; 16 348 360 (Pubitemid 32105416)
20. Cundy T, Davidson J, Rutland M D, Stewart C, DePaoli A M. Recombinant osteoprotegerin for juvenile Pagets disease. N Engl J Med: 2005; 353 918 923 (Pubitemid 41247931)
21. Burgess T, Qian Y X, Kaufman S, Ring B D, Van G, Capparelli C, Kelley M, Hsu H, Boyle W J, Dunstan C R, Hu S, Lacey D L. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol: 1999; 145 527 538 (Pubitemid 29215717)
22. Lacey D L, Tan H L, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess T L, Boyle W J, Polverino A J. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol: 2000; 157 435 448 (Pubitemid 30626907)
23. Seeman E, Delmas P D, Hanley D A, Sellmeyer D, Cheung A M, Shane E, Kearns A, Thomas T, Boyd S K, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res: 2010; 25 1886 1894
24. Mosekilde L, Weisbrode S E, Safron J A, Stills H F, Jankowsky M L, Ebert D C, Danielsen C C, Sogaard C H, Franks F, Stevens M L, Paddock C L, Boyce R W. Evaluation of the skeletal effects of combined mild dietary calcium restriction and ovariectomy in Sinclair S-1 minipigs: a pilot study. J Bone Miner Res: 1993; 8 1311 1321 (Pubitemid 23321694)
25. Klopfenstein C, Farmer C, Martineau G-P. Diseases of the Mammary Gland. In: Straw B E, Zimmerman J J, DAllaire S, Taylor D J. (eds) Diseases of Swine. Iowa Blackwell Publishing: 2006; 57 86
26. Chang W, Tu C, Chen T H, Bikle D, Shoback D. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal: 2008; 1 1
27. Reid I R, Miller P D, Brown J P, Kendler D L, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese M A, Woodson G, Bone H, Ding B, Wagman R B, San Martin J, Ominsky M S, Dempster D W. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res: 2010; 25 2256 2265
28. Redd E H, Miller S C, Jee W S. Changes in endochondral bone elongation rates during pregnancy and lactation in rats. Calcif Tissue Int: 1984; 36 697 701 (Pubitemid 15173947)
29. Miller S C, Shupe J G, Redd E H, Miller M A, Omura T H. Changes in bone mineral and bone formation rates during pregnancy and lactation in rats. Bone: 1986; 7 283 287 (Pubitemid 17195788)
30. Bekker P J, Holloway D L, Rasmussen A S, Murphy R, Martin S W, Leese P T, Holmes G B, Dunstan C R, DePaoli A M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res: 2004; 19 1059 1066 (Pubitemid 41110556)
31. Jin Q, Cirelli J A, Park C H, Sugai J V, Taba M, Kostenuik P J, Giannobile W V. RANKL inhibition via osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol: 2007; 78 1300 1308
32. Pierroz D D, Bonnet N, Baldock P A, Ominsky M S, Stolina M, Kostenuik P J, Ferrari S L. Are osteoclasts needed for the bone anabolic response to PTH? A study of intermittent PTH with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem: 2010; 285 28164 28173
33. Baron R, Ferrari S, Russel R G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone: 2011; 48 677 692